ABSTRACT BACKGROUND: Promotion of prescription drug coupons and vouchers by pharmaceutical manufacturers has increased in recent years. These coupons and vouchers usually subsidize patients' cost-sharing obligations. In other words, drug companies pay for a patient's portion of the drug cost, and the remaining cost is paid by the patient and the patient's health plan. This practice is normally used for brand name drugs but can and has been used for generic drugs. Copayments (also known as copays), and especially high copays for higher cost drugs, are used by managed care organizations (MCOs) to place a higher financial burden on patients and also provide an appreciation of the medication cost. At the same time, tiered copay plans offer incentives, in the form of lower copays, to use available equivalent generic alternatives or lower cost brand name drugs, instead of high cost brand name drugs. With higher tiered copays for brand name drugs being offset by coupons, little is known about MCO representatives' perceptions about the use of copay subsidy coupons for brand name prescription drugs.
METHODS: A 28-item online survey instrument was used to collect data from health plan and PBM representatives. A sample of 834 MCO representatives was selected from the Academy of Managed Care Pharmacy membership directory. Pharmacists, managers, directors, and executive officers working in pharmacy, formulary, and clinical pharmacy operations were selected for the survey. Respondents from non-MCO settings and government-sponsored health plans were excluded from the survey.
RESULTS: A total of 122 surveys were returned after 3 emails (i.e., an invitation and 2 reminder emails) of which 105 were usable surveys, giving a response rate of 13.7%. A 5-point, 11-item Likert scale (1 = Strongly Disagree and 5 = Strongly Agree) was used to measure respondents' perceptions toward prescription drug coupons. Some items referred to coupons used repeatedly over a year to get copay discounts (i.e., longterm use coupons) whereas some items referred to coupons distributed for trial purposes (i.e., short-term use coupons). Of the 105 respondents, 100 (95.2%) agreed that copay subsidy coupons encouraged nonpreferred brand name drugs over preferred brand name drugs. A total of 102 (97.2%) respondents agreed that brand name drug coupons undermined tiered formulary structure. Ninety-two (87.6%) respondents agreed that short-term use coupons increased plan sponsor's costs while 96 (91.5%) respondents agreed that sponsor cost increased with long-term use coupons. A total of 68 (64.8%) agreed that short-term use coupons should be eliminated whereas 78 (74.3%) respondents agreed that long-term use coupons should be eliminated.
• One of the drug promotion tactics employed by pharmaceutical companies is using coupons for brand name drugs.
• Drug coupons subsidize copayments for brand name drugs of patients enrolled in private prescription drug plans.
• Tiered copayment structures are used as incentives by managed care organizations (MCOs) to control brand name drug utilization and costs by encouraging patients to choose equivalent generic options placed in lowest tier.
• By subsidizing copayments, drug coupons circumvent the patient's financial responsibility for higher copayments on brand name drugs.
• Little is known about perceptions of MCOs' representatives toward prescription drug coupons.
What is already known about this subject
• This is an exploratory study, using survey methodology, to determine perceptions of prescription drug coupon use by MCO representatives (i.e., health plans and pharmacy benefit managers.) • The survey findings show that MCO respondents mostly agreed that copay subsidy coupons encouraged nonpreferred brands, undermined tiered formulary structure, increased brand name drug utilization, and increased plan sponsor costs.
• The survey found that very few MCO respondents indicated that their organizations monitored the use of and costs incurred by using prescription drug coupons.
• The survey reported mixed responses in MCO respondents' perceptions about whether prescription drug coupons use increase patients' adherence and persistence with their drug therapy. 
What this study adds
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consumer groups, MCOs, and policymakers have begun to criticize pharmaceutical companies for such brand name drug coupon offers, on the grounds that these efforts circumvent the intent of higher copayments-to deter use of a higher cost drug (per formulary)-and increase brand name drug utilization. 14 Furthermore, research has shown that the presence of prescription drug coupons is associated with favorable consumer attitudes toward the advertisement and the brand, increasing the likelihood that patients will inquire about these drugs at the doctor's office. 15 On the other hand, pharmaceutical manufacturers claim that patients enrolled in voucher programs show higher adherence and persistence rates. LoyaltyScript, a cardbased loyalty program by McKesson, has shown that using copay cards improves patients' persistence rates. 7 Furthermore, previous studies have shown that lowering out-of-pocket costs increases medication adherence.
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Objectives
The primary research objective was to determine the perception of managers and executives from MCOs, including pharmacy benefit management (PBMs) organizations, toward the use of prescription drug copay subsidy coupons. Secondary objectives were to determine if managed care providers, such as PBMs and health plans, monitor the costs incurred due to drug coupons; to determine their perceptions as to whether drug coupons increased primary adherence and persistence; and to determine what strategy MCOs have to address the use of drug coupons or vouchers.
■■ Methods
A 28-item online survey instrument was used to collect information from health plan and PBM representatives. A convenience sample of 834 MCO representatives was selected from the Academy of Managed Care Pharmacy (AMCP) membership for the year 2010-2011. The AMCP membership directory lists more than 6,000 members; the selection criteria for inclusion in the study were based on employment in private (for-profit) health plans or PBMs and by employment position within the organization. The sample comprised pharmacists, managers, directors, and executive officers working in pharmacy, formulary, and clinical pharmacy operations. Respondents from non-MCO settings, federal government-sponsored health plans such as Medicaid and Medicare, state-sponsored health plans, the pharmaceutical industry, and Massachusetts state private health plans were excluded from the study.
The survey instrument was created by the researchers and reviewed for clarity and completeness by 4 MCO representatives working as clinical directors and clinical managers in health plans and PBM organizations. This study was conducted after receiving approval from the Institutional Review Board at the University of Texas at Austin. MCO representatives were contacted via e-mail, which contained an explanation of the study and provided a link to the questionnaire. Data were T he practice of using coupons for promoting health care products dates back to 1894. The first drug promoted using a coupon was Coca Cola, 1 which was then a patented drug stated to have tonic and nerve stimulant properties. Over the past century, coupons were extensively used for marketing consumer goods. However, the earliest use of coupons for prescription drugs started in the 1980s when the prescription drug Rufen (ibuprofen) was promoted using rebate coupons. 2 In the 1990s, chain pharmacies started offering copay subsidy coupons, and Tagamet (cimetidine) was promoted using copay-waiving coupons. 3, 4 As managed care organizations (MCOs) increase patient cost sharing, the use of copay subsidies continues to increase, as well. Many pharmaceutical companies are providing drug coupons and vouchers to subsidize patients' cost-sharing obligations whether they take the form of copayments, coinsurance, or deductibles. 5 Health insurers, plans, and pharmacy benefit managers (PBMs) have implemented tiered copayment benefits for prescription drugs. A report by the Pharmacy Benefit Management Institute (2011) highlights an increase in the expansion of cost-sharing approaches. MCOs are employing benefit designs that have increased formulary tiers from the traditional 3-tier design (generics, preferred brands, and nonpreferred brands) to 5 or more tiers that also include specialty and lifestyle drugs. The report mentions 85% of employers used a formulary design with 3 or more tiers in 2010. 6 Furthermore, in the retail pharmacy class of trade, the average difference in copayment increased over the previous year by 4.5% for preferred brands, 7.6% for nonpreferred brands, and 12.4% for the lifestyle drug tier. Average copayments in 3-, 4-, and 5-tier plan designs have increased, except for the generic and specialty drug categories. 6 Health insurance providers have used such tiered designs as an incentive for their plan members to choose the least costly equivalent drugs whenever possible, such as generics over their brand name equivalents. However, the amount of copayments for brand name drugs has increased for tiered designs over years. Pharmaceutical companies are claiming that drug coupons help overcome accessibility and affordability to new drug options. 7, 8 In addition, due to patent expiry of brand name patents, there is increased generic competition. 9 These factors have led to increased promotion of brand name drugs through the distribution of drug coupons.
Drug coupons may take the form of paper coupons, vouchers, or copay cards. 10 Today, electronic coupons are available that can be directly applied toward patients' copayments.
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Drug coupons are offered for brand name drugs used in treating chronic conditions such as asthma, allergy, depression, and hypercholesterolemia. 12 In addition, drug coupons have been offered for lifestyle drugs used to treat erectile dysfunction, insomnia, skin conditions such as acne and alopecia, and for birth control. 13 Typically, these brand name drugs have no generic equivalent and are placed in higher tiers in formularies, with higher copay responsibilities for patients. Many
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collected using SurveyMonkey (Palo Alto, CA). Data collection began on July 12, 2011, and continued until August 11, 2011. A total of 3 e-mail contacts were made (invitation and 2 reminder e-mails) to all targeted participants. In this survey, a copay subsidy coupon was defined as a promotional financial incentive such as a coupon, voucher, or copay card that waives the patient's copayment partially or completely. The instrument was divided into 3 sections. Section 1 comprised items asking about MCO representatives' experiences with coupons and included questions to capture data about their awareness of drug coupons and perceptions about them, approaches used in marketing, the change in number of drug coupons compared with previous year, opinions on top brand name drugs that were promoted using drug coupons, and monitoring and costs incurred by MCOs due to coupons. Section 2 measured perceptions about whether the use of copay subsidy coupons has an impact on brand name drug utilization, brand loyalty, costs, and patient adherence. A 5-point Likert scale (1 = Strongly Disagree to 5 = Strongly Agree) was used to assess perceptions toward copay subsidy coupons. This section also assessed opinions about whether drug coupons should be eliminated. In this section, some items were categorized as either long-term or short-term use coupons. For the purpose of this survey, long-term use coupons were defined as copay cards that could be used repeatedly over a year to get discounts on refills, while short-term use coupons were defined as copay cards distributed for trial offers. Section 3 collected demographic data such as MCO type, pharmacy licensure, position within organization, and number of beneficiaries enrolled in the organization.
Data were analyzed using Predictive Analytics Software (PASW), version 18, formerly known as Statistical Package for the Social Studies (SPSS, Inc., Chicago). Statistical significance was set at an alpha level of 0.05. Descriptive analyses (means, standard deviations, frequency distributions) were used for all variables in the instrument.
■■ Results Analysis of Survey Response
Of the 834 MCO representatives contacted via e-mail, 767 MCO representatives were assumed to have received the survey. This number was calculated after taking into consideration 60 e-mails that were not successfully delivered and excluding 7 respondents who indicated they worked for governmentsponsored health plans or state plans. A total of 122 surveys were completed and returned, after 3 e-mails, of which 105 were usable, giving a response rate of 13.7% (105/767).
Respondents' Characteristics
Of the 105 usable responses, 79 (75.2%) were from health plan employees. A majority of MCO representatives, 100 (95.2%), were licensed pharmacists. In terms of current position in the organization, 56 (53.3%) were directors, 26 (24.8%) were program managers, 14 (13.3%) were pharmacists, and 9 (8.6%) were executive officers. Fifty (47.6%) MCO representatives worked for health plans that had a total enrollment of fewer than 1 million lives within their organization (Table 1) .
MCO Representatives' Perceptions of Copay Subsidy Coupons
Descriptive statistics of MCO respondents' perceptions of copay subsidy coupons for brand name prescription drugs are presented in Table 2 . Of the 105 MCO respondents, a total of 85 (80.9%) respondents either agreed or strongly agreed that patients are more likely to shift from generic to brand name drugs when they receive copay subsidy coupons. Only 10 (9.5%) respondents disagreed. When asked to respond to the statement "Copay subsidy coupons increase utilization of brand name prescription drugs instead of generic drugs," a total of 99 (95.2%) respondents either agreed or strongly agreed with the statement. For the item that addressed whether copay subsidy coupons encouraged nonpreferred brand name drugs over preferred brand name drugs, 42 (40%) respondents agreed, and 58 (55.2%) representatives strongly agreed.
MCO respondents expressed some disagreement about whether use of both short-term use and long-term use coupons contribute to consistent use of brand name drugs and brand loyalty. Nineteen (18.1%) respondents disagreed with the statement "The majority of patients who take advantage of short-term use copay subsidy coupons become regular users of brand name drugs," whereas 15 (14.5%) respondents disagreed 
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that short-term use copay subsidy coupons build brand loyalty toward brand name prescription drugs. A total of 102 (97.2%) respondents opined that brand name drug coupons undermined tiered formulary structure. In responding to the item measuring opinions regarding primary adherence, "Copay subsidy coupons improve the likelihood that patients will get their first prescription filled," 50 (48.1%) agreed, while 14 (13.4%) disagreed with the statement. Patient persistence was measured by the statement "Copay subsidy coupons improve likelihood that patient will obtain refill prescription." Some 22 (20.9%) respondents disagreed while 45 (42.9%) respondents agreed. A total of 68 (64.8%) either agreed or strongly agreed that short-term use coupons should be eliminated, whereas 78 (74.3%) respondents agreed or strongly agreed that long-term use coupons should be eliminated.
MCO Representatives' Beliefs Regarding Change in Number of Copay Subsidy Coupons
The MCO representatives were asked if they believed the number of copay subsidy coupons offered by pharmaceutical manufacturers increased, decreased, or stayed about the same as compared with the previous year. A total of 91 (86.7%) of the 105 respondents believed that the number of copay subsidy coupons had increased as compared with the previous year, 13 (12.4%) indicated that it had stayed about the same, and 1 (1.0%) believed that it decreased. Forty-seven (44.8%) respondents indicated that 10 or more of the top 20 brand name drugs use coupon promotions. Respondents also ranked most widely used marketing approaches for prescription drug coupons, with the top 3 identified as physicians (n = 90, 85.7%), Internet offers (n = 74, 70.5%), and magazine coupons (n = 60, 57.1%).
Monitoring Copay Subsidy Coupons by MCOs
MCO representatives were asked to indicate whether their organization monitored the use of drug coupons, or if their organization contracted with another organization to monitor drug coupon use. Table 3 shows that 24 (22.9%) of the 105 MCO respondents indicated that their organization does monitor coupon/vouchers for brand name prescriptions, and 95 respondents (90.5%) indicated that they did not contract another organization to monitor use of coupons. 
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MCO representatives were asked to indicate if their organization monitored costs incurred due to use of prescription drug coupons. A total of 23 respondents (21.3%) indicated that they do monitor costs incurred by coupon or voucher use.
MCO Respondents' Discussion on Ways to Discourage Coupons
In an effort to determine how managed care firms discourage the use of coupons or vouchers, respondents were asked: "In your opinion, please specify the ways in which the use of copay subsidy coupons could be discouraged." Respondents were given 5 selections, and they could check all that apply. The 5 choices were: (a) Increase the difference in cost sharing between generic and nonformulary drugs (b) Use a step-therapy approach (defined as the use of secondline therapy after trial with the first-line therapy) (c) Use adherence rewards to encourage the use of generics (d) Don't know (e) Other (please specify)
A total of 98 (93.3%) of the 105 respondents answered the question with a total of 196 responses. The top choice was the use of step therapy; it was selected by 89 respondents (90.8%) ( Table 4) .
■■ Discussion
In this survey of MCO representatives' perceptions about prescription drug copay subsidy coupons, findings show that MCO respondents are very aware of prescription drug coupons and problems they raise for their organizations. Most of the MCO respondents believed that copay subsidy coupons offered by pharmaceutical manufacturers had increased in 2011 as compared with 2010. This finding was supported in a recent article published in Dow Jones Newswires that notes there were 310 copay card programs in 2011-a rise of 260% over the previous 2 years. 17 The coupon offers are widely seen in magazine ads and newspapers, or are offered at physician offices. In this survey, MCO respondents ranked physicians and the Internet among the mostly widely used sources for coupon distribution. It is possible that a significant number of patients receive coupons along with trial samples at physician offices. 18 Internet search results for prescription drugs direct an information seeker to a manufacturer-sponsored web homepage 19 or to a drug coupon website that has an alphabetical listing of discounted prescription drugs. Such promotions are short term for introducing products or may last for a year (long term). Respondents indicated that 10 or more of the top 20 brand name drugs are promoted using coupons. This finding is consistent with the Weppner et al. study (2009) that notes more than 30 out of the 50 most prescribed brand name drugs have Internet offers for coupons or vouchers. 19 The survey showed that a low proportion of responding MCOs monitored their members' use and costs incurred due to coupons, and the majority of respondents did not contract with other organizations to monitor coupon/voucher use. These findings suggest that monitoring coupon use may involve substantial extra time and added cost that may be prohibitive, or that there is no way to capture the data. The downside is that without the monitoring data, MCO managers must rely on perceptions, which may or may not be correct. It should be noted that the vast majority of prescription claims databases do not collect or track pharmaceutical coupon use. Many times MCOs do not know who paid the required copay: patient, drug coupon, or pharmacy voucher.
MCO respondents perceived that copay subsidy coupons affected the utilization of generic drugs and increased brand name drug utilization. In addition, the majority of respondents agreed that copay subsidy coupons encouraged use of nonpreferred brand name drugs instead of preferred brand name drugs. Literature suggests that incentive-based formulary structures provide cost savings for health plans. 20 However, with copay subsidy coupons off-setting out-of-pocket costs on nonpreferred or nonformulary brand name drugs for plan members, the patient has no incentive to choose generic or preferred brand name drugs. While respondents agreed that coupon use may decrease generic use at times, one counterargument in favor of copay subsidy coupons pointed out that 
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"the intensity of copay card use has no relationship to generic uptake." In fact, for 15 of the largest commercial payers, copay card use was not correlated with generic utilization. 21 MCO respondents agreed that even short-term use coupons were effective in drawing brand-loyal regular users of brand name prescription drugs. This finding is not consistent with previous consumer behavior studies that suggest short-term coupon users are deal-prone and may revert back to their original brands when deals are withdrawn. 22, 23 In cases of longterm use copay subsidy coupons, MCO respondents perceived that promotions for longer periods of time were responsible for increasing the number of regular users and brand loyalty toward brand name prescriptions.
MCO respondents unanimously agreed that coupons (short term and long term) increased costs to plan sponsors. When MCO respondents' were asked if "Copay subsidy coupons improve the likelihood that patients will get their first prescription filled," only 11 respondents answered that they strongly agreed. This finding is interesting because relatively fewer respondents agreed that coupons are effective marketing tools, and they increase patients' chances of acquiring new prescription drugs. The results also showed that there was an even split among respondents who responded that they were neutral and those who said they agreed with this statement. This finding reflects that although pharmacy and over-the-counter coupon promotion have proven to be effective in driving consumers to purchase products, skepticism remains about whether prescription drug coupons are effective marketing tools. 24 A similar finding was noted for the item "Copay subsidy coupons improve the likelihood of refill." Drug manufacturers suggest that drug coupons are part of patient-directed programs used to reduce patients' financial burden, which may lead to increased adherence. 7, 25 Patient-directed programs such as LoyaltyScript have shown higher persistence rates among enrolled patients. 7 Previous studies have noted that an increase in prescription drug copays decreases medication adherence, 26, 27 and reduction in out-of-pocket costs can improve medication adherence. 16 Thus, copay-lowering drug coupons are incentives to consumers to fill prescriptions. This study finding suggests that MCO respondents may not have considered the potential positive effects of prescription drug coupons on adherence. Furthermore, these findings contradict earlier statements in this survey. When asked if patients using coupons become regular users or brand-loyals for long-term use coupons, a greater proportion of MCO respondents agreed. In terms of perception of copay subsidy coupon elimination, a majority of respondents agreed or strongly agreed that both short-term and long-term coupons should be eliminated. However, a few respondents disagreed or had neutral opinions, indicating that not all MCO representatives dislike drug coupons. A possible explanation could be that some MCO representatives may welcome drug coupons for expensive specialty drugs. An article in Drug Benefit News points out that although health plans should adopt strategies to counteract some prescription copay subsidy coupons, they should partner with pharmaceutical companies on costly treatments that use specialty drugs. 28 MCO respondents unanimously agreed that copay subsidy coupons undermine efforts to manage drug costs based on a tiered formulary structure. In particular, MCO representatives were sensitive to copay subsidy coupon promotion, with a majority believing that coupons should be eliminated. The majority of MCO respondents indicated that their organization discussed ways to discourage copay subsidy coupon use within the past year, and when MCO respondents were asked to specify ways in which coupons can be discouraged, a majority favored using a step-therapy approach. In addition, respondents indicated that MCOs should omit coverage for drugs with coupons, start their own coupon incentive programs for generic and preferred drugs, or use mandatory mail order service. Overall, MCO respondents wanted drug coupons to be eliminated but believed that complete elimination was beyond their control.
Limitations
As a self-administered questionnaire research project, this survey has limitations. First, the findings of this survey cannot be generalized because it used a convenience sample of the AMCP membership; the sample size was relatively small; and the response rate was marginal. This survey used a sample from the AMCP directory, which could introduce selection bias; thus, it may be possible that AMCP members have different perspectives than the general MCO population. Second, this survey assessed perceptions of MCO representatives of copay subsidy coupons, and perceptions may evolve or change with time. Hence, we are not assured that MCO representatives may have the same views today as they did when the survey was conducted. In addition, as with all self-administered questionnaires, there may be differences in interpreting the items or questions. Third, the study response rate was low (i.e., 13.7%). It is possible that some organizations may prohibit access to survey links or prohibit their employees from participation in surveys due to corporate web use policies. Fourth, a nonresponse bias was not accounted for in this study. Nonrespondent MCO representatives may have different perceptions of copay subsidy coupons than those who did respond.
■■ Conclusion
This exploratory survey touched upon the sensitive topic of prescription drug copay subsidy coupons and provides limited insight into the perceptions of MCO representatives about the effects of copay coupons on formulary integrity. Although copay subsidy coupons may provide cost-saving options for patients by providing easy access to expensive and new brand name drugs, MCO representatives believe their use leads to increased brand name drug utilization and undermines their formulary controls, thereby driving up plan sponsor cost.
